Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > 10years ago

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Sep 17, 2024 7:22pm

56 Views

Post# 36228159

RE:RE:RE:RE:RE:RE:RE:RE:RE:10years ago

They can't go for very long with the interest on the balloon lown and the fix cost from their in house sales team if they run out of Egrifta for one or two quarters. I don't see it at the moment. I don't see how we get out of this one.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023